Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level

Figures & data

Table 1 Comparison of Baseline Data Between the Two Groups of Patients

Basic Data Information	Control Group (n=88)	Observation Group (n=88)	t/x²	P
Gender			0.052	0.818
Male	44	42
Female	44	46
Age	65.13±3.79	65.32±3.86	0.216	0.829
Duration of diabetes (years)	17.34±2.69	17.21±2.58	0.215	0.830
Duration of diabetic nephropathy (years)	2.19±0.61	2.25±0.64	0.418	0.6176
Disease stage			0.220	0.688
Phase II	49	47
Phase III	39	41
BMI (kg/m^2)	24.69±0.42	24.73±0.38	0.334	0.724
FPG (mmol/L)	8.65±0.77	8.54±0.79	0.935	0.351
2hPG (mmol/L)	12.27±2.41	12.31±2.43	0.109	0.913
HbAlc (%)	7.86±0.88	7.91±0.85	0.382	0.702
Scr (μmol/L)	89.59±5.71	89.77±5.54	0.212	0.832
BUN (mmol/L)	17.68±3.26	17.55±3.31	0.263	0.793
UmAlb (mg/L)	248.32±5.36	248.35±5.21	0.037	0.970
UAER (μg/min)	158.36±12.18	158.41±12.24	0.027	0.978
UACR (mg/g)	178.32±12.56	178.42±12.45	0.053	0.958
24 h urine protein quantification (mg/24h)	289.94±16.85	291.31±16.77	0.541	0.589

Table 2 Comparison of Clinical Treatment Efficacy Between the Two Groups of Patients

Group	Number of Cases	Markedly Effective	Efficient	Invalid	Total Effective Rate (%)
Control group	88	25	45	18	79.55%
Observation group	88	32	54	2	97.73%
x²	–	–	–	–	4.537
P	–	–	–	–	0.033

Figure 1 Comparison of blood glucose indicators between the two groups of patients. (A) FPG levels. (B) 2hPG levels. (C) HbAlc levels.

Note: *Means comparison P<0.05.

Figure 2 Comparison of renal function indicators between the two patient groups. (A) Scr levels. (B) BUN levels. (C) UmAlb levels. (D) UAER levels. (E) UACR levels. (F) 24h urine protein quantification level.

Note: *Indicates comparison P<0.05.

Figure 3 Comparison of inflammatory marker indices between two groups of patients. (A) Levels of hs-CRP. (B) Levels of IL-1β. (C) Levels of TNF-α.

Note: *Indicates comparison P<0.05.

Table 3 Comparison of Adverse Reactions Between the Two Groups

Adverse Reactions	Control Group (n=88)	Observation Group (n=88)	x²	P
Ketoacidosis	2	0	–	–
Hypoglycemia	10	3	–	–
Feel sick and vomit	4	2	–	–
Dizziness headache	3	0	–	–
Total incidence (%)	21.59%	5.68%	4.155	0.037